Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EBP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EBP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EBP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EBP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EBP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EBP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EBP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005134618 | Oral cavity | OSCC | negative regulation of hydrolase activity | 182/7305 | 379/18723 | 1.98e-04 | 1.32e-03 | 182 |
GO:19026523 | Oral cavity | OSCC | secondary alcohol metabolic process | 79/7305 | 147/18723 | 1.98e-04 | 1.33e-03 | 79 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
GO:001095117 | Oral cavity | OSCC | negative regulation of endopeptidase activity | 126/7305 | 252/18723 | 2.37e-04 | 1.54e-03 | 126 |
GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
GO:007121910 | Oral cavity | OSCC | cellular response to molecule of bacterial origin | 112/7305 | 221/18723 | 2.64e-04 | 1.69e-03 | 112 |
GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
GO:00311008 | Oral cavity | OSCC | animal organ regeneration | 45/7305 | 76/18723 | 2.83e-04 | 1.79e-03 | 45 |
GO:001046618 | Oral cavity | OSCC | negative regulation of peptidase activity | 130/7305 | 262/18723 | 2.89e-04 | 1.82e-03 | 130 |
GO:00432006 | Oral cavity | OSCC | response to amino acid | 64/7305 | 116/18723 | 2.96e-04 | 1.86e-03 | 64 |
GO:00161262 | Oral cavity | OSCC | sterol biosynthetic process | 39/7305 | 64/18723 | 3.12e-04 | 1.94e-03 | 39 |
GO:190303715 | Oral cavity | OSCC | regulation of leukocyte cell-cell adhesion | 162/7305 | 336/18723 | 3.39e-04 | 2.08e-03 | 162 |
GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
GO:003600317 | Oral cavity | OSCC | positive regulation of transcription from RNA polymerase II promoter in response to stress | 18/7305 | 24/18723 | 3.73e-04 | 2.28e-03 | 18 |
GO:004563720 | Oral cavity | OSCC | regulation of myeloid cell differentiation | 106/7305 | 210/18723 | 4.58e-04 | 2.76e-03 | 106 |
GO:00712304 | Oral cavity | OSCC | cellular response to amino acid stimulus | 42/7305 | 71/18723 | 4.59e-04 | 2.76e-03 | 42 |
GO:00303248 | Oral cavity | OSCC | lung development | 91/7305 | 177/18723 | 5.18e-04 | 3.01e-03 | 91 |
GO:005110120 | Oral cavity | OSCC | regulation of DNA binding | 64/7305 | 118/18723 | 5.53e-04 | 3.21e-03 | 64 |
GO:19021059 | Oral cavity | OSCC | regulation of leukocyte differentiation | 136/7305 | 279/18723 | 5.53e-04 | 3.21e-03 | 136 |
GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EBP | SNV | Missense_Mutation | rs782423797 | c.208N>T | p.Ala70Ser | p.A70S | Q15125 | protein_coding | tolerated(0.07) | possibly_damaging(0.489) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-E9-A1NG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-EW-A1J3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
EBP | deletion | Frame_Shift_Del | novel | c.170delC | p.Pro57HisfsTer22 | p.P57Hfs*22 | Q15125 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EBP | SNV | Missense_Mutation | rs28935174 | c.440N>A | p.Arg147His | p.R147H | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A6-A56B-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | PD |